Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):August 26, 2004
Avanir Pharmaceuticals
001-15803
(Commission File Number)
California | 33-0314804 | |
(State or other jurisdiction of | (I.R.S. Employer Identification No.) | |
incorporation) |
11388 Sorrento Valley Road, Suite 200, San Diego, California 92121
(858) 622-5200
Not applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | ||||||||
Item 9.01 Financial Statements and Exhibits | ||||||||
SIGNATURES | ||||||||
EXHIBIT 3.2 |
Table of Contents
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
On August 26, 2004, the registrant amended and restated its Bylaws. A copy of the Amended and Restated Bylaws is attached hereto as Exhibit 3.2.
Item 9.01 Financial Statements and Exhibits
Exhibit | Description | |
3.2 | Amended and Restated Bylaws, adopted August 26, 2004 | |
-2-
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Avanir Pharmaceuticals | ||||
Date: September 1, 2004 | By: | /s/ Gregory P. Hanson | ||
Gregory P. Hanson, CMA | ||||
Chief Financial Officer | ||||
-3-